MX382673B - Biomarcadores predictivos y para prognosis relacionados con terapia anti-angiogénica de cáncer colorrectal metastasico. - Google Patents
Biomarcadores predictivos y para prognosis relacionados con terapia anti-angiogénica de cáncer colorrectal metastasico.Info
- Publication number
- MX382673B MX382673B MX2017003387A MX2017003387A MX382673B MX 382673 B MX382673 B MX 382673B MX 2017003387 A MX2017003387 A MX 2017003387A MX 2017003387 A MX2017003387 A MX 2017003387A MX 382673 B MX382673 B MX 382673B
- Authority
- MX
- Mexico
- Prior art keywords
- vegf
- colorectal cancer
- metastatic colorectal
- predictive
- subjects
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462051091P | 2014-09-16 | 2014-09-16 | |
| US201562099630P | 2015-01-05 | 2015-01-05 | |
| PCT/US2015/049279 WO2016044041A1 (en) | 2014-09-16 | 2015-09-10 | Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017003387A MX2017003387A (es) | 2018-01-30 |
| MX382673B true MX382673B (es) | 2025-03-13 |
Family
ID=54207741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017003387A MX382673B (es) | 2014-09-16 | 2015-09-10 | Biomarcadores predictivos y para prognosis relacionados con terapia anti-angiogénica de cáncer colorrectal metastasico. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10525104B2 (enExample) |
| EP (1) | EP3194974B1 (enExample) |
| JP (1) | JP6692358B2 (enExample) |
| KR (1) | KR102471057B1 (enExample) |
| CN (1) | CN107076749B (enExample) |
| AU (1) | AU2015318207B2 (enExample) |
| CA (1) | CA2960890A1 (enExample) |
| EA (1) | EA036671B1 (enExample) |
| IL (1) | IL250905B (enExample) |
| MX (1) | MX382673B (enExample) |
| WO (1) | WO2016044041A1 (enExample) |
| ZA (1) | ZA201701664B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2971054A4 (en) | 2013-03-14 | 2017-04-12 | Otraces Inc. | A method for improving disease diagnosis using measured analytes |
| WO2015200905A2 (en) | 2014-06-28 | 2015-12-30 | Oligasis, Llc | Dual pdgf/vegf antagonists |
| IL290457B2 (en) | 2015-12-30 | 2025-02-01 | Kodiak Sciences Inc | Antibodies and their conjugates |
| CA3011988A1 (en) | 2016-01-22 | 2017-07-27 | Otraces Inc. | Systems and methods for improving disease diagnosis |
| WO2018181881A1 (ja) * | 2017-03-31 | 2018-10-04 | 株式会社Ｈｉｒｏｔｓｕバイオサイエンス | がん患者の治療効果の予測および／または再発モニタリング |
| US11524053B2 (en) | 2018-01-26 | 2022-12-13 | The Regents Of The University Of California | Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents |
| CA3092588A1 (en) | 2018-03-02 | 2019-09-06 | Kodiak Sciences Inc. | Il-6 antibodies and fusion constructs and conjugates thereof |
| WO2020165483A1 (es) * | 2019-02-15 | 2020-08-20 | Universidad de Córdoba | Método de predicción de respuesta a tratamiento del cáncer con agentes antiangiogénicos |
| US20210012899A1 (en) * | 2019-07-13 | 2021-01-14 | Otraces, Inc. | Diagnosis for various diseases using tumor microenvironment active proteins |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| US12656349B2 (en) | 2019-10-17 | 2026-06-16 | Board Of Regents, The University Of Texas System | Measurement of bevacizumab-insensitive vascular endothelial growth factor-a |
| CN114867487A (zh) | 2019-11-25 | 2022-08-05 | 加利福尼亚大学董事会 | 用于眼内新生血管的长效vegf抑制剂 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| US7396664B2 (en) | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
| CN101283280A (zh) * | 2005-08-18 | 2008-10-08 | Zadec私人有限公司 | 用于诊断结直肠癌的蛋白质标记和所述标记作为所述癌症类型治疗的药物靶点的用途 |
| AU2010282274A1 (en) * | 2009-08-14 | 2012-03-15 | Allergan, Inc. | Methods of treating cancer using growth factor retargeted endopeptidases |
| WO2011089101A1 (en) | 2010-01-19 | 2011-07-28 | F. Hoffmann-La Roche Ag | Tumor tissue based biomarkers for bevacizumab combination therapies |
| CN104634971A (zh) | 2010-07-19 | 2015-05-20 | 霍夫曼-拉罗奇有限公司 | 鉴定响应抗癌疗法的可能性升高的患者的方法 |
| JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
-
2015
- 2015-09-10 WO PCT/US2015/049279 patent/WO2016044041A1/en not_active Ceased
- 2015-09-10 JP JP2017533704A patent/JP6692358B2/ja active Active
- 2015-09-10 EP EP15771819.8A patent/EP3194974B1/en active Active
- 2015-09-10 CN CN201580049558.1A patent/CN107076749B/zh active Active
- 2015-09-10 US US15/509,461 patent/US10525104B2/en active Active
- 2015-09-10 MX MX2017003387A patent/MX382673B/es unknown
- 2015-09-10 CA CA2960890A patent/CA2960890A1/en active Pending
- 2015-09-10 AU AU2015318207A patent/AU2015318207B2/en active Active
- 2015-09-10 EA EA201790549A patent/EA036671B1/ru unknown
- 2015-09-10 KR KR1020177007326A patent/KR102471057B1/ko active Active
-
2017
- 2017-03-02 IL IL250905A patent/IL250905B/en active IP Right Grant
- 2017-03-08 ZA ZA2017/01664A patent/ZA201701664B/en unknown
-
2019
- 2019-11-21 US US16/690,459 patent/US11439683B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL250905A0 (en) | 2017-04-30 |
| JP2017530372A (ja) | 2017-10-12 |
| CN107076749B (zh) | 2020-12-29 |
| KR102471057B1 (ko) | 2022-11-28 |
| MX2017003387A (es) | 2018-01-30 |
| US10525104B2 (en) | 2020-01-07 |
| EA201790549A1 (ru) | 2017-07-31 |
| ZA201701664B (en) | 2018-05-30 |
| US20200129589A1 (en) | 2020-04-30 |
| KR20170055972A (ko) | 2017-05-22 |
| CN107076749A (zh) | 2017-08-18 |
| US20170281725A1 (en) | 2017-10-05 |
| JP6692358B2 (ja) | 2020-05-13 |
| EP3194974A1 (en) | 2017-07-26 |
| WO2016044041A1 (en) | 2016-03-24 |
| US11439683B2 (en) | 2022-09-13 |
| AU2015318207B2 (en) | 2021-11-04 |
| IL250905B (en) | 2019-12-31 |
| EA036671B1 (ru) | 2020-12-07 |
| CA2960890A1 (en) | 2016-03-24 |
| AU2015318207A1 (en) | 2017-04-06 |
| EP3194974B1 (en) | 2019-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201790549A1 (ru) | Предиктивные и прогностические биомаркеры, связанные с антиангиогенной терапией злокачественной опухоли | |
| CY1122233T1 (el) | Μεθοδος για την προβλεψη του αποτελεσμaτος μιας θεραπειας με αφλιβερσεπτη ενος ασθενους με υποψια οτι πασχει απο καρκινο | |
| MX2017008421A (es) | Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga. | |
| BR112017020893A2 (pt) | método para o tratamento de câncer | |
| EA201790019A1 (ru) | Способ выбора персонализированной трехкомпонентной терапии для лечения рака | |
| EP3606507A4 (en) | SEROLOGICAL BIOMARKERS FOR EARLY DIAGNOSIS OF LUNG CANCER | |
| EA201791578A1 (ru) | Панель биомаркеров для обнаружения рака | |
| MX392040B (es) | Estandares de antigeno prostatico y sus usos. | |
| PE20160192A1 (es) | Composiciones y metodo para tratar condiciones asociadas con el complemento | |
| BR112016017112A2 (pt) | Composições de apilimod e métodos de uso das mesmas | |
| BR112017008799A2 (pt) | composições de apilimod e métodos de uso das mesmas no tratamento de câncer renal | |
| CL2015000192A1 (es) | Método de seleccion de un sujeto que padece un tumor maligno para tratamiento con inhibidor de jak/stat que comprende determinar nivel de expresión de biomarcadores. | |
| MX384423B (es) | Biomarcadores para la respuesta a inhibidores del mejorador del homólogo 2 de zeste (ezh2). | |
| MX381948B (es) | Composiciones y metodos para determinar el pronostico de cancer de endometrio. | |
| DK3250708T3 (da) | Biomarkører for kolorektal cancer-relaterede sygdomme | |
| MX2016015163A (es) | Biomarcadores mit y metodos para su uso. | |
| MX2018005867A (es) | Integracion de las caracteristicas tumorales con el indice de cancer de mama. | |
| EA201891478A1 (ru) | Способы и композиции для оценки риска возникновения рака | |
| BR112016015595A2 (pt) | métodos de determinação de câncer de pulmão | |
| EP3490547A4 (en) | TREATMENT METHOD | |
| MA40636A (fr) | Procédés pour détecter le cancer de la prostate | |
| MX2015013197A (es) | Biomarcadores de la respuesta farmacodinamica tumoral. | |
| MX2018009112A (es) | Metodo para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cancer mediante la medicion del nivel de un biomarcador plasmatico. | |
| EP3111223C0 (en) | LUNG CANCER BIOMARKERS, METHODS AND KITS THEREOF | |
| WO2018074865A3 (ko) | 유방암 예후 예측용 조성물 및 방법 |